The program aims to help people in the U.S. access the Eversense E3 continuous glucose monitor (CGM) more affordably. It offers major savings for eligible individuals looking to experience the benefits of the long-term, implantable CGM.
Eversense E3, a 180-day CGM, requires two sensor insertion and removal procedures per year. It offers a mean absolute relative difference (MARD — an accuracy metric for CGMs) of 8.5%. The system features predictive on-body alerts to never miss a critical event. Senseonics develops the sensor and Ascensia serves as the global exclusive distributor for Eversense E3.
Senseonics also has the regulatory wheels in motion for Eversense E3 with a 365-day wear time. The company expects an “imminent” submission to the FDA.
About the expanded program for the Senseonics CGM
Under the expanded PASS program guidelines, eligible individuals pay $99 out of pocket for an unlimited number of six-month Eversense E3 systems. That equals an average monthly cost of $16.50 and a total out-of-pocket cost under $200 for each year of CGM use. This excludes the costs of insertion and removal.
Eligible participants must have a commercial insurance plan, with or without Eversense E3 coverage. This excludes government insurance as a primary or secondary coverage or commercial plans that require direct purchases from HCPs.
Senseonics introduced Eversense PASS in April 2022 when it launched the Eversense E3 system. Last May, the company extended the $99 offer to cover a whole year of CGM.
“Traditional, short-term CGMs don’t work for everyone, and we are proud to bring a truly unique CGM option in Eversense E3 to people with diabetes,” said Rudy Thoms, VP of CGM for commercial U.S. at Ascensia Diabetes Care. “We are significantly extending the Eversense PASS program to provide major savings for people in the U.S., beyond when they first try the 6-month CGM to their subsequent Eversense E3 CGM systems.
“We believe that long-term CGMs are the future, and so we are pleased to further improve access to and affordability of Eversense, allowing more people to experience the future today.”
